ReviewHematology. American Society of Hematology. Education Program2019
The growing landscape of FLT3 inhibition in AML.
Review in Hematology. American Society of Hematology. Education Program, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 citations in OpenAlex.
- Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.Blood · 2021Trial
- BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemia.Annals of hematology · 2026Article
- Decursin induces FLT3-ITD acute myeloid leukemia cell apoptosis by increasing the expression of the ubiquitin-conjugase UBE2L6.Cell communication and signaling : CCS · 2025Article
- FLT3 inhibitor maintenance after allogeneic stem cell transplantation inAnnals of translational medicine · 2024Article
- Review
- Article
- Downregulation of RCN1 promotes pyroptosis in acute myeloid leukemia cells.Molecular oncology · 2023Article
- Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment.Hematology reports · 2023Review
- Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data.Healthcare (Basel, Switzerland) · 2023Article
- Set Protein Is Involved in FLT3 Membrane Trafficking.Cancers · 2023Article
- Article
- "FLipping" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors.Cancers · 2022Review
- Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia.Experimental hematology · 2022Review
- AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to killHaematologica · 2022Article
- Increasing Role of Targeted Immunotherapies in the Treatment of AML.International journal of molecular sciences · 2022Review
- Role of Biomarkers in FLT3 AML.Cancers · 2022Review
- The research progress of targeted therapy in acute myeloid leukemia based on bibliometric analysis.Frontiers in oncology · 2022Review
- Towards precision medicine for AML.Nature reviews. Clinical oncology · 2021Review
- The contribution of single-cell analysis of acute leukemia in the therapeutic strategy.Biomarker research · 2021Review
- Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Midostaurin and gilteritinib are FLT3 inhibitors that have been recently approved for use in FLT3-mutant acute myeloid leukemia (AML). These approved drugs represent a new standard of care for patients with FLT3 mutations in both the first-line and salvage settings. The success of midostaurin used in combination with induction chemotherapy has prompted exploration of newer, more potent and targeted inhibitors (including gilteritinib) in the first-line setting in combination with chemotherapy. At the same time, the success of gilteritinib and other newer FLT3 inhibitors as monotherapy in the salvage setting has been tempered by the development of resistance because of diverse mechanisms. Investigational strategies that incorporate FLT3 inhibitors in combination with hypomethylating agents and as maintenance therapy after allogeneic stem cell transplantation have shown promise. Other novel combination strategies are also undergoing clinical investigation. In this article, we review the current landscape of approved and investigational FLT3 inhibitors in AML, including the current standard of care and investigational strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.